Commerzbank Aktiengesellschaft’s Gilead Sciences GILD Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-125,000	Closed	-$697K	–	911
2019 Q2	$697K	Buy	125,000 +98,000	+363%	+$6.45M	0.01%	683
2019 Q1	$399K	Sell	27,000 -46,300	-63%	-$3.08M	﹤0.01%	664
2018 Q4	$1.19M	Hold	73,300	–	–	0.01%	508
2018 Q3	$467K	Buy	+73,300	New	+$5.54M	﹤0.01%	701
2015 Q1	–	Sell	-230,000	Closed	-$21.7M	–	1180
2014 Q4	$21.7M	Buy	+230,000	New	+$23.8M	0.14%	126
2014 Q1	–	Sell	-8,200	Closed	-$661K	–	1268
2013 Q4	$661K	Buy	+8,200	New	+$571K	﹤0.01%	982
2013 Q3	–	Sell	-83,700	Closed	-$4.29M	–	1341
2013 Q2	$4.29M	Buy	+83,700	New	+$4.36M	0.02%	587

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Commerzbank Aktiengesellschaft's GILD Position: Q1 2026 in Review

Commerzbank Aktiengesellschaft reduced its Gilead Sciences (GILD) stake by 17% in Q1 2026, selling an estimated $1.57M and leaving 54,756 shares worth $7.63M. The position accounts for 0.16% of the portfolio, ranked #69.

Commerzbank Aktiengesellschaft first reported a position in GILD in Q2 2013 and has held it in 39 quarters since. The position peaked at $173M in Q3 2014. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Commerzbank Aktiengesellschaft held 54,756 shares of Gilead Sciences worth $7.63M as of Q1 2026.
Commerzbank Aktiengesellschaft sold 11,222 Gilead Sciences shares in Q1 2026, an estimated $1.57M.
Gilead Sciences made up 0.16% of Commerzbank Aktiengesellschaft's portfolio in Q1 2026, its #69 holding.
Commerzbank Aktiengesellschaft first reported a position in Gilead Sciences in Q2 2013 and has held it in 39 quarters since.
Commerzbank Aktiengesellschaft's Gilead Sciences position peaked at $173M in Q3 2014.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q1 2026, filed 7 May 2026.